# Sanara MedTech Inc. to Participate in the TD Cowen 46th Annual Health Care Conference on March 3rd
Canonical URL: https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-participate-in-the-td-cowen-46th-annual-health-care-confer-3dda8e6f
Ticker: SMTI
Company: Sanara MedTech
Source: Sanara MedTech
Published: 2026-02-17 12:30 EST
## Summary

Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology...

## Article Body
Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the TD Cowen 46th Annual Health Care Conference, which is being held at the Boston Marriott Copley Place in Boston, MA from March 2 – 4, 2026. Management will deliver a presentation to investors on Tuesday, March 3 at approximately 9:10 a.m. Eastern Time.

The presentation materials for the conference will be posted to the Company’s investor relations website, https://ir.sanaramedtech.com/ , prior to the presentation. A live audio webcast of the presentation will also be accessible under the “Events” section of the Company’s Investor Relations website at https://ir.sanaramedtech.com/ . An archive of the webcast will be available for replay following the conference.

About Sanara MedTech Inc.

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX ® Surgical Activated Collagen ® Powder, BIASURGE ® Advanced Surgical Solution, FORTIFY TRG ® Tissue Repair Graft and FORTIFY FLOWABLE ® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN ® Verified Inductive Bone Matrix, ALLOCYTE ® Plus Advanced Viable Bone Matrix, BiFORM ® Bioactive Moldable Matrix and TEXAGEN ® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com .

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
## Recent Company News
- 2026-05-11 20:50 EST — [Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-first-quarter-2026-financial-results-unaudited-60a52bab) — Source: Sanara MedTech
- 2026-04-14 11:30 EST — [Sanara MedTech Inc. to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-first-quarter-2026-financial-results-on-may-12-2026-6f13f45d) — Source: Sanara MedTech
- 2026-03-24 11:00 EST — [Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-reports-fourth-quarter-unaudited-and-full-year-2025-financial-4054944c) — Source: Sanara MedTech
- 2026-03-11 11:30 EST — [Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-announces-publication-of-peer-reviewed-study-evaluating-the-e-7ca921f2) — Source: Sanara MedTech
- 2026-03-03 12:30 EST — [Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026](https://biopharmsignal.com/news/SMTI/sanara-medtech-inc-to-report-fourth-quarter-and-full-year-2025-financial-results-df95bb20) — Source: Sanara MedTech
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)